Pharmacokinetic/pharmacodynamic correlation in therapy MCQs With Answer
This question set is designed for M.Pharm students to deepen understanding of pharmacokinetic–pharmacodynamic (PK/PD) relationships and their application in therapeutic drug monitoring (TDM) and dose optimization. The MCQs cover core concepts—PK/PD indices (AUC/MIC, Cmax/MIC, %T>MIC), concentration- vs time-dependent effects, free drug considerations, steady state and loading doses, population PK, Monte Carlo simulations, and clinical adjustment strategies in renal/hepatic impairment. Each question emphasizes interpretation of PK/PD data and practical decision-making for safer, more effective therapy. Use these questions to test critical thinking and readiness for clinical pharmacokinetics practice.
Q1. What is the fundamental goal of pharmacokinetic/pharmacodynamic (PK/PD) correlation in therapy?
- To predict adverse drug reactions based on patient history
- To relate drug exposure to pharmacologic effect and optimize dosing
- To design novel drug molecules with improved potency
- To standardize laboratory assay methods for drug measurement
Correct Answer: To relate drug exposure to pharmacologic effect and optimize dosing
Q2. Which PK/PD index is most predictive of efficacy for aminoglycoside antibiotics?
- % Time the drug concentration exceeds MIC (%T>MIC)
- AUC over 24 hours divided by MIC (AUC24/MIC)
- Peak concentration divided by MIC (Cmax/MIC)
- Minimum inhibitory concentration alone (MIC)
Correct Answer: Peak concentration divided by MIC (Cmax/MIC)
Q3. For a time-dependent antibiotic such as a beta-lactam, which dosing strategy maximizes bacterial killing?
- Single large bolus dose once daily to maximize Cmax
- Prolonged or continuous infusion to maximize %T>MIC
- Intermittent high peaks with long dosing intervals
- Decreasing doses to reduce toxicity risk
Correct Answer: Prolonged or continuous infusion to maximize %T>MIC
Q4. In TDM, why is unbound (free) drug concentration often more relevant than total concentration?
- Free drug concentrations are easier to measure in routine labs
- Only unbound drug is pharmacologically active and able to cross membranes
- Total concentration does not change with dose adjustments
- Protein binding always increases toxicity and must be minimized
Correct Answer: Only unbound drug is pharmacologically active and able to cross membranes
Q5. Which PK parameter primarily determines the time to reach steady state for a drug given at regular intervals?
- Volume of distribution (Vd)
- Clearance (Cl)
- Elimination half-life (t1/2)
- Bioavailability (F)
Correct Answer: Elimination half-life (t1/2)
Q6. When is a loading dose indicated in PK/PD-guided therapy?
- When a drug has a very short half-life and rapid onset is unnecessary
- When immediate attainment of target concentration is required due to long half-life
- Only for drugs administered orally to increase absorption
- When clearance is very high and frequent maintenance doses are planned
Correct Answer: When immediate attainment of target concentration is required due to long half-life
Q7. A drug exhibits non-linear (capacity-limited) elimination. Which statement is correct for PK/PD considerations?
- Doubling the dose will always double the plasma concentration
- Small dose changes can cause disproportionate concentration changes; monitoring is essential
- Half-life remains constant regardless of dose
- Protein binding changes predictably with dose
Correct Answer: Small dose changes can cause disproportionate concentration changes; monitoring is essential
Q8. Which PK/PD target would you prioritize for vancomycin to predict clinical efficacy against S. aureus?
- Cmax/MIC ratio above 10
- %T>MIC greater than 50%
- AUC24/MIC of at least 400
- Minimal inhibitory concentration below 2 mg/L only
Correct Answer: AUC24/MIC of at least 400
Q9. In population PK/PD and Monte Carlo simulations, what primary output helps clinicians choose dosing regimens?
- Predicted adverse event reports per 100 patients
- Probability of target attainment (PTA) across MIC distributions
- Average protein binding values in the population
- Standardized bioavailability for all formulations
Correct Answer: Probability of target attainment (PTA) across MIC distributions
Q10. Which factor most commonly necessitates dose reduction of renally cleared drugs to avoid toxicity?
- Low protein binding
- Reduced glomerular filtration rate (GFR)
- Increased hepatic enzyme activity
- Elevated Vd due to obesity
Correct Answer: Reduced glomerular filtration rate (GFR)
Q11. What is hysteresis in PK/PD relationships?
- A rapid equilibration between plasma and effect site concentrations
- A time delay between plasma concentration changes and pharmacodynamic effect, producing a loop on concentration–effect plot
- An irreversible drug–receptor binding phenomenon leading to tolerance
- An artifact caused by poor assay sensitivity
Correct Answer: A time delay between plasma concentration changes and pharmacodynamic effect, producing a loop on concentration–effect plot
Q12. For drugs with high plasma protein binding, which change most affects free concentration and pharmacologic effect?
- A change in formulation from tablet to IV
- Displacement from binding sites by another highly protein-bound drug
- An increase in Vd due to muscle wasting
- A proportional increase in elimination half-life only
Correct Answer: Displacement from binding sites by another highly protein-bound drug
Q13. Which sampling strategy is most appropriate for routine TDM when monitoring trough concentrations for efficacy and toxicity?
- Random sampling at any time post-dose
- Peak sampling 15 minutes after infusion
- Sampling immediately before the next scheduled dose (trough)
- Sampling at exactly half the dosing interval only
Correct Answer: Sampling immediately before the next scheduled dose (trough)
Q14. A drug shows concentration-dependent killing and a significant post-antibiotic effect (PAE). Which dosing tactic is best?
- Continuous infusion to maintain low steady concentrations
- Frequent small doses to keep %T>MIC high
- Intermittent high-dose therapy to maximize Cmax and exploit PAE
- A dose reduction to avoid toxicity even if Cmax decreases
Correct Answer: Intermittent high-dose therapy to maximize Cmax and exploit PAE
Q15. When interpreting AUC-based TDM, which patient factor most directly affects AUC assuming dose unchanged?
- Bioavailability variability due to first-pass metabolism
- Change in clearance (Cl)
- Change in Vd without clearance change
- Time of day when the drug is administered
Correct Answer: Change in clearance (Cl)
Q16. Which statement best describes PK/PD breakpoint selection for an antimicrobial?
- Breakpoints are fixed values that do not consider PK variability
- Breakpoints combine MIC distributions, PK exposures achievable, and PD targets to categorize susceptibility
- Breakpoints are based solely on in vitro enzyme activity assays
- Breakpoints are identical worldwide regardless of dosing practices
Correct Answer: Breakpoints combine MIC distributions, PK exposures achievable, and PD targets to categorize susceptibility
Q17. A patient with hypoalbuminemia receives a highly protein-bound antiepileptic. What PK/PD implication is most likely?
- Total plasma concentration will rise while free concentration falls
- Free (active) concentration will increase despite lower total concentration, potentially increasing effect/toxicity
- Drug clearance will be unaffected; no dose change required
- Bioavailability will be markedly reduced
Correct Answer: Free (active) concentration will increase despite lower total concentration, potentially increasing effect/toxicity
Q18. Which method helps to individualize dosing in patients with high interindividual variability using sparse concentration data?
- Population pharmacokinetic modeling with Bayesian forecasting
- Simple linear extrapolation from average patient data
- Using fixed dose adjustments based on weight alone
- Relying solely on published mean AUC targets
Correct Answer: Population pharmacokinetic modeling with Bayesian forecasting
Q19. In PK/PD studies, the MIC is determined under standardized conditions. Which limitation should clinicians consider when applying MIC to patient therapy?
- MIC values account for host immune function and infection site penetration
- In vitro MIC does not reflect dynamic concentration changes or protein binding in vivo
- All isolates of a species have identical MICs
- MIC measurement replaces the need for PK monitoring
Correct Answer: In vitro MIC does not reflect dynamic concentration changes or protein binding in vivo
Q20. Which therapeutic scenario best illustrates the need to integrate PK/PD, TDM, and clinical context rather than relying on a single concentration value?
- Stable patient on a drug with low variability and wide therapeutic index
- Critically ill patient with augmented renal clearance receiving a time-dependent antibiotic where %T>MIC target is uncertain
- Outpatient on once-daily medication with well-established dosing
- Use of topical therapy where systemic exposure is negligible
Correct Answer: Critically ill patient with augmented renal clearance receiving a time-dependent antibiotic where %T>MIC target is uncertain
